This brochure from Ace Therapeutics comprehensively shows our preclinical capabilities in diabetes research and highlights our commitment to advancing the frontiers of diabetes and its complications research. Through integrated end-to-end solutions, we assist pharmaceutical partners and academic institutions in accelerating the development of novel antidiabetic drugs and improving research efficiency.
Our Capabilities
Advanced Technology Platform
A systematic introduction to Ace Therapeutics' preclinical capabilities and cutting-edge technology platforms.
Ace Therapeutics offers a diverse portfolio of rodent models and services for depression research.
Ace Therapeutics utilizes advanced platform to help clients deliver data-rich insights in preclinical psychiatric studies.
The PCP-induced model uses NMDA antagonist PCP to mimic core schizophrenia symptoms in animals, studying disease mechanisms and treatments.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
